Cargando…
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis
INTRODUCTION: The once-daily long-acting muscarinic antagonist (LAMA) tiotropium and once-daily long-acting β(2)-agonist (LABA) olodaterol have been studied as a once-daily fixed-dose combination (FDC) in patients with chronic obstructive pulmonary disease (COPD). Two large, 52-week, double-blind, p...
Autores principales: | Ferguson, Gary T., Fležar, Matjaž, Korn, Stephanie, Korducki, Lawrence, Grönke, Lars, Abrahams, Roger, Buhl, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486785/ https://www.ncbi.nlm.nih.gov/pubmed/26112656 http://dx.doi.org/10.1007/s12325-015-0218-0 |
Ejemplares similares
-
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015) -
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016) -
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(®) and OTEMTO(®) studies: a subgroup analysis by age
por: Ferguson, Gary T, et al.
Publicado: (2016) -
Effect of tiotropium and olodaterol on symptoms and
patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
por: Ferguson, Gary T., et al.
Publicado: (2017) -
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)